Log in
NASDAQ:SNBP

Sun BioPharma Stock Forecast, Price & News

$3.10
+0.11 (+3.68 %)
(As of 09/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.07
Now: $3.10▼
$3.37
50-Day Range
$2.49
MA: $5.12▼
$9.50
52-Week Range
$2.37
Now: $3.10▼
$10.00
Volume50,233 shs
Average Volume29,221 shs
Market Capitalization$29.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.36 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNBP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.sunbiopharma.com
Phone952-479-1196

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees4
Outstanding Shares9,614,000
Market Cap$29.80 million
Next Earnings DateN/A
OptionableNot Optionable
$3.10
+0.11 (+3.68 %)
(As of 09/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SNBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sun BioPharma (NASDAQ:SNBP) Frequently Asked Questions

How has Sun BioPharma's stock price been impacted by Coronavirus (COVID-19)?

Sun BioPharma's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNBP shares have decreased by 35.6% and is now trading at $3.10.
View which stocks have been most impacted by COVID-19.

Who are some of Sun BioPharma's key competitors?

Some companies that are related to Sun BioPharma include Actinium Pharmaceuticals (ATNM), Catabasis Pharmaceuticals (CATB), Obseva (OBSV), Strongbridge Biopharma (SBBP), Corvus Pharmaceuticals (CRVS), Adamas Pharmaceuticals (ADMS), Lumos Pharma (LUMO), Zosano Pharma (ZSAN), Inflarx (IFRX), Sierra Oncology (SRRA), Leap Therapeutics (LPTX), SUMMIT THERAPEU/S (SMMT), Tonix Pharmaceuticals (TNXP), 9 Meters Biopharma (NMTR) and Aclaris Therapeutics (ACRS).
View all competitors.

What other stocks do shareholders of Sun BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sun BioPharma investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Processa Pharmaceuticals (PCSA), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), Humanigen (HGEN) and Kaleido Biosciences (KLDO).

Who are Sun BioPharma's key executives?

Sun BioPharma's management team includes the following people:
  • Dr. Michael T. Cullen Jr., Co-Founder, Exec. Chairman, Pres & CEO (Age 73)
  • Ms. Susan Horvath, VP of Fin., CFO, Sec. & Treasurer (Age 60)
  • Dr. Thomas X. Neenan, Co-Founder & Chief Scientific Officer
  • Ms. Tammy Groene, VP of Operations
  • Dr. Suzanne Gagnon, Chief Medical Officer & Director (Age 62)

What is Sun BioPharma's stock symbol?

Sun BioPharma trades on the NASDAQ under the ticker symbol "SNBP."

When does Sun BioPharma's quiet period expire?

Sun BioPharma's quiet period expires on Wednesday, October 7th. Sun BioPharma had issued 2,545,454 shares in its public offering on August 28th. The total size of the offering was $10,487,270 based on an initial share price of $4.12. During Sun BioPharma's quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Sun BioPharma?

Shares of SNBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sun BioPharma's stock price today?

One share of SNBP stock can currently be purchased for approximately $3.10.

How big of a company is Sun BioPharma?

Sun BioPharma has a market capitalization of $29.80 million. Sun BioPharma employs 4 workers across the globe.

What is Sun BioPharma's official website?

The official website for Sun BioPharma is www.sunbiopharma.com.

How can I contact Sun BioPharma?

Sun BioPharma's mailing address is 712 VISTA BLVD 305, WACONIA MN, 55387. The company can be reached via phone at 952-479-1196 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.